Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gamida Cell stock

Own Gamida Cell stock in just a few minutes.

Fact checked

Gamida Cell Ltd is a biotechnology business based in the US. Gamida Cell shares (GMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Gamida Cell employs 79 staff and has a market cap (total outstanding shares value) of USD$566.5 million.

How to buy shares in Gamida Cell

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Gamida Cell. Find the stock by name or ticker symbol: GMDA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gamida Cell reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Gamida Cell, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Gamida Cell. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Gamida Cell share price

Use our graph to track the performance of GMDA stocks over time.

Gamida Cell shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$2.7296 - USD$12.47
50-day moving average USD$9.5594
200-day moving average USD$6.766
Wall St. target priceUSD$19.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.203

Buy Gamida Cell shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Gamida Cell stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gamida Cell financials

Gross profit TTM USD$0
Return on assets TTM -38.27%
Return on equity TTM -100.68%
Profit margin 0%
Book value $1.222
Market capitalisation USD$566.5 million

TTM: trailing 12 months

Shorting Gamida Cell shares

There are currently 724,804 Gamida Cell shares held short by investors – that's known as Gamida Cell's "short interest". This figure is 32.2% up from 548,463 last month.

There are a few different ways that this level of interest in shorting Gamida Cell shares can be evaluated.

Gamida Cell's "short interest ratio" (SIR)

Gamida Cell's "short interest ratio" (SIR) is the quantity of Gamida Cell shares currently shorted divided by the average quantity of Gamida Cell shares traded daily (recently around 724804). Gamida Cell's SIR currently stands at 1. In other words for every 100,000 Gamida Cell shares traded daily on the market, roughly 1000 shares are currently held short.

However Gamida Cell's short interest can also be evaluated against the total number of Gamida Cell shares, or, against the total number of tradable Gamida Cell shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gamida Cell's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Gamida Cell shares in existence, roughly 10 shares are currently held short) or 0.0199% of the tradable shares (for every 100,000 tradable Gamida Cell shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gamida Cell.

Find out more about how you can short Gamida Cell stock.

Gamida Cell share dividends

We're not expecting Gamida Cell to pay a dividend over the next 12 months.

Gamida Cell share price volatility

Over the last 12 months, Gamida Cell's shares have ranged in value from as little as $2.7296 up to $12.47. A popular way to gauge a stock's volatility is its "beta".

GMDA.US volatility(beta: 2.02)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gamida Cell's is 2.0241. This would suggest that Gamida Cell's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Gamida Cell overview

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site